Celcuity keeps cool amid questions about Revtorpyk launch timing

After investors blanched last month at a slower-than-expected launch timeline for Celcuity’s novel breast cancer med Revtorpyk, the company used much of its latest earnings call to address concerns over—and reaffirm confidence in—the pace of its expected rollout.